Doxorubicin에 과민반응을 보인 유방암 환자에서 성공적으로 시행한 Epirubicin 탈감작 요법 1예
Successful Desensitization to Epirubicin in a Breast Cancer Patient with Doxorubicin Hypersensitivity
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Doxorubicin, a chemotherapeutic agent of the anthracycline family, has commonly been used to treat a wide range of cancers including leukemia, Hodgkin’s lymphoma, and cancers of the breast, uterus, ovary and bladder. Hypersensitivity is a rare adverse reaction to anthracyclines including daunorubicin, idarubicin and epirubicin. Although cross-reactivity among chemotherapeutic agents of the anthracycline family is not completely established, these agents are not clinically recommended if a patient has show hypersensitivity reaction to any anthracyclines. Desensitization is an alternative treatment option to overcome hypersensitivity reaction to anthracyclines, but cases of anthracycline desensitization have rarely been reported till now. We report successful epirubucin desensitization in a breast cancer patient with doxorubicin hypersensitivity.
Abstract
Doxorubicin, a chemotherapeutic agent of the anthracycline family, has commonly been used to treat a wide range of cancers including leukemia, Hodgkin’s lymphoma, and cancers of the breast, uterus, ovary and bladder. Hypersensitivity is a rare adverse reaction to anthracyclines including daunorubicin, idarubicin and epirubicin. Although cross-reactivity among chemotherapeutic agents of the anthracycline family is not completely established, these agents are not clinically recommended if a patient has show hypersensitivity reaction to any anthracyclines. Desensitization is an alternative treatment option to overcome hypersensitivity reaction to anthracyclines, but cases of anthracycline desensitization have rarely been reported till now. We report successful epirubucin desensitization in a breast cancer patient with doxorubicin hypersensitivity.
참고문헌 (17)
- Apetoh L, "Immunogenicity of anthracyclines: moving towards more personalized medicine", Trends Mol Med, 14, pp.141~151 (2008)
- Shepherd GM, "Hypersensitivity reactions to chemotherapeutic drugs", Clin Rev allergy Immunol, 24, pp.253~262 (2003)
- Lee CW, "Rapid inpatient", outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses, 2005, pp.99, 393~399
- Zanotti KM, "Prevention and management of antineoplastic-inducedhypersensitivityreactions", Drug Saf, 24, pp.767~779 (2001)
- Greenberger PA, "Pretreatment of high-risk patients requiring radiographic contrast media studies", J Allergy Clin Immunol, 67, pp.185~187 (1981)
- Trudeau ME, "Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-clinical Trials Group", J Clin Oncol, 14, pp.422~428 (1996)
- Verweij J, "Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind", Ann Oncol, 5, pp.495~505 (1994)
- Wendel GD Jr, "Penicillin allergy and desensitization in serious infections during pregnancy", N Engl J Med, 312, pp.1229~1232 (1985)
- Robinson JB, "Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies", Gynecol Oncol, 82, pp.550~558 (2001)
- Castells MC, "Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases", J Allergy Clin Immunol, 122, pp.574~580 (2008)
- Castells M, "Rapid desensitization for hypersensitivity reactions to chemotherapy agents", Curr Opin Allergy Clin Immunol, 6, pp.271~277 (2006)
- Castells M, "Desensitization for drug allergy", Curr Opin Allergy Clin Immunol, 6, pp.476~481 (2006)
- Kepley CL, "Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels", Int Arch Allergy Immunol, 138, pp.29~39 (2005)
- Morales AR, "Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen", Ann Allergy Asthma Immunol, 94, pp.575~580 (2005)
- Souhami L, "Urticaria following intravenous doxorubicin administration", JAMA, 240, pp.1624~1626 (1978)
- Crowther D, "Management of adult acute myelogenous leukaemia", Br Med J, 1, pp.131~137 (1973)
- Rose PG, "Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity", Gynecol Oncol, 89, pp.429~433 (2003)